<DOC>
	<DOCNO>NCT01521065</DOCNO>
	<brief_summary>The purpose study confirm clinical economic benefit IRay treatment respect number anti-VEGF injection frequency visit first year treatment patient wet Age-related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>An Open-label Study Evaluate Clinical Economic Benefits I-Ray Patients With Choroidal Neovascularization Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description>The objective study confirm clinical economic benefit low voltage external beam radiotherapy IRay respect number anti-VEGF injection frequency ophthalmic assessment one year interval follow treatment subject neovascular AMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Must neovascular AMD receive antiVEGF injection within 1 month prior enter study , need treatment antiVEGF therapy . Must total lesion size &lt; 12 disc area CNV lesion great linear dimension &lt; 6 mm , great 3 mm center fovea furthest point lesion perimeter . Must provide informed consent , document writing , give copy sign informed consent form . Must willing able return schedule treatment followup examination 3year duration study . Must least 50 year age . Women must postmenopausal â‰¥1 year surgically sterilize . Must best correct visual acuity great equal 24 letter study eye least 20 letter fellow eye ( eyes meet study criterion , eye bad vision select study eye ) . Present implanted device , device label specifically contraindicate subject undergoing xrays . An axial length &lt; 20 mm ( limitation IRay device ) &gt; 26 mm ( exclude subject pathologic myopia ) . Evidence diabetes retinal finding consistent diabetic retinopathy , retinopathy cause . Prior concurrent therapy study eye age related macular degeneration ( intravitreal antiVEGF ) , include submacular surgery , subfoveal thermal laser photocoagulation ( without photographic evidence ) , transpupillary thermotherapy ( TTT ) ocular photodynamic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
</DOC>